The Latest

This Week in HIV Research: HIV Is Not an Obstacle

April 11, 2019: acute syphilis and virologic control; neuropsychological performance after switching off efavirenz; structural LGBTQ stigma and HIV criminalization in U.S. states; lung cancer resection surgery in people with HIV.

By Barbara Jungwirth and Myles Helfand

Dolutegravir More Effective Than Efavirenz at Achieving Viral Suppression During Late-Term Pregnancy, New Study Shows

Unlike some previous studies that focused on early pregnancy, this study showed no associated congenital disabilities with either drug.

By Sony Salzman

This Week in HIV Research: How Low (an Atripla Dose) Can You Go?

Atripla may be just as effective when taken every other day; poor antiretroviral prescription fill rates after hospitalization; U.S. progress against UNAIDS targets; hepatitis C transmission clustering in France.

By Barbara Jungwirth and Myles Helfand

This Week in HIV Research: The Science of Risk

Traditional factors vs. HIV-specific factors in non-communicable complications; frailty and fracture risk among women; lipid measurements and coronary risks; new data on efavirenz and birth defects.

By Barbara Jungwirth and Myles Helfand

This Week in HIV Research: Check Your Frailty

The link between frailty and chronic disease development; Atripla’s long-term efficacy; the dangers of restrictive eligibility criteria for hepatitis C treatment; nicotine metabolism rates in people living with HIV.

By Barbara Jungwirth and Myles Helfand

Complera Non-Inferior to Atripla and Better Tolerated, Study Finds

The STaR study compared Complera to Atripla and found that Complera was not only non-inferior to Atripla, it performed better in terms of HIV symptoms and quality of life.

By Barbara Jungwirth

Antiretroviral Rounds: Resistance on Two Fronts

Got this challenging curbside consult from a colleague, and it has a interesting wrinkle:

I have a longstanding patient with HIV who had many failed regimens in the 1990's with resultant following mutations on a genotype done in 2003:

NRTI (M1...

By Paul E. Sax, M.D. for NEJM Journal Watch

Complera and Atripla News

Last summer, 48-week data won FDA approval for Complera (see the November/December 2011 "Briefly" for the complicated details). At IDSA, 96-week data were presented from the ECHO and THRIVE studies that pitted the new Complera against Atripla. Comple...

By Jeff Berry and Enid Vazquez for Positively Aware

Switching From Atripla to Complera

Now that the best-selling Atripla has a real competitor, an important question becomes, can people switch from Atripla to the new Complera?

While switching to a new and improved drug or regimen is common, there was a concern about switching here bec...

By Jeff Berry and Enid Vazquez for Positively Aware

ICAAC HIV Poster Roundup #1: Clinically Relevant Findings

Here's a quick sampling of some of the more noteworthy HIV-related posters presented at a major research conference last week. Topics covered include a surprisingly high frequency of people quitting Atripla due to side effects; the decline of multidr...

By Myles Helfand